Lupus & antiphospholipid syndrome
The impact of anti-SSA/Ro antibodies on pregnancy outcomes in patients with systemic lupus erythematosus
Authors' conclusion
aPL showed an association with foetal loss in SLE, while anti-SSA/Ro antibodies did not.
Study context
- Population
- First pregnancies after SLE onset, Lupus Registry of Nationwide Institutions (LUNA, 2016–2022)
- Participants
- 247 pregnancies
- Exposure
- Anti-SSA/Ro positive vs negative
- Anti-SSA/Ro positiven = 145
- Anti-SSA/Ro negativen = 102reference
- Outcome
- Adverse pregnancy outcomes (foetal loss)
Methodological detailsregistry-based (LUNA), multivariate logistic regression adjusted for aPL
- Registry-based (LUNA)
- Multivariate logistic regression adjusted for aPL
Main finding
As reported in the abstract
Foetal loss (multivariate logistic regression)
Odds ratio (95% CI)
aPL
2.46(1.21–5.01)
History of methylprednisolone pulse
2.89(1.39–6.00)
anti-SSA/Ronot associated
1.32(0.64–2.74)
Observational data: associations, not effects.
Further findings
Live birth
P = 0.64
Preterm birth
P = 0.87
Small for gestational age infants (small subgroup)
P = 0.11
Low birthweight infants (small subgroup)
P = 0.25
Birthweight (small subgroup)
P = 0.20
Original publication
The impact of anti-SSA/Ro antibodies on pregnancy outcomes in patients with systemic lupus erythematosus. Rheumatology (Oxford). Published 16 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →